Dexcom has opted not to raise its FY26 revenue outlook due to the current geopolitical environment.

DexCom, Inc. DXCM reported first-quarter 2026 adjusted earnings per share (EPS) of 56 cents, which beat the Zacks Consensus ...

DexCom Inc (DXCM) reports a robust 15% revenue increase, driven by international demand and strategic product launches, despite challenges in the US market.

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...

SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...

DexCom (DXCM) delivered earnings and revenue surprises of +19.66% and +1.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Dexcom G7 CGMs contain a complex electronic assembly within a wearable package that stands up to the rigors of everyday ...

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...

Is DXCM a good stock to buy? We came across a bullish thesis on DexCom, Inc. on Part-Time Compounder’s Substack by Francesco ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc (DXCM). (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program ...